Watson Pharmaceuticals Inc

Type: Company
Name: Watson Pharmaceuticals Inc
First reported Oct 18 2014 - Updated Oct 18 2014 - 1 reports

Actavis plc Raised to “Outperform” at Zacks (ACT)

Actavis plc (NYSE:ACT)Zacks’ analyst wrote, "Actavis’ second quarter results were once again strong with the company beating on both the top- and bottom-line. Earnings grew 70.1% to $3.42 per share, beating the Zacks Consensus Estimate of $3.37. Revenues ... [Published American Banking News - Oct 18 2014]
First reported Oct 07 2014 - Updated Oct 07 2014 - 1 reports

Actavis, Jazz, Novo Lead Top World Stocks List

The U.S. market is in a correction, but drugmakers are showing broad resilience. On IBD's Top World Stocks list, drugmakers represent three of 10 issues. Two of those are based in Ireland. One is in Denmark. New Jersey-based Watson Pharmaceuticals bought ... [Published Crawford Financial Planning - Oct 07 2014]
First reported Oct 06 2014 - Updated Oct 06 2014 - 1 reports

25 Young Companies in the Money

2014 to date has been the best year since the 2007–09 recession for young biopharmas dreaming of securing big money as the financial markets have finally warmed to drug or diagnostic developers, whether they raised private money as on this list, went ... [Published Genetic Engineering News - Oct 06 2014]
First reported Sep 30 2014 - Updated Sep 30 2014 - 2 reports

Trxade : Advances to Direct Sales Model Utilizing Existing Pharmaceutical Network

- Tr x ade Group, Inc. ( OTCQB : TRXD ), a web-based pharmaceutical marketplace engaged in promoting and enabling trade among independent pharmacies and large pharmaceutical suppliers nationally, announced the launch of our new direct sales model through ... [Published 4 Traders - Sep 30 2014]
First reported Sep 29 2014 - Updated Sep 29 2014 - 2 reports

Acura Pharmaceuticals Hydrocodone Bitartrate With Acetaminophen Tablets Meet Clinical Endpoints

PALATINE, IL -- (Marketwired) -- 09/29/14 -- Acura Pharmaceuticals Inc. (NASDAQ: ACUR) announced today preliminary results from three clinical studies for its abuse deterrent AVERSION® hydrocodone bitartrate with acetaminophen (AVERSION H/A) development ... [Published Pettinga Financial Advisors - Sep 29 2014]
First reported Sep 24 2014 - Updated Sep 24 2014 - 1 reports

Third Circuit Rejects Presumption of Irreparable Harm in Lanham Act Cases

The Third Circuit ruled in Ferring Pharmaceuticals v. Watson Pharmaceuticals on August 26 that “a party seeking a preliminary injunction in a Lanham Act case is not entitled to a presumption of irreparable harm but rather is required to demonstrate that ... [Published JD Supra - Sep 24 2014]
First reported Sep 23 2014 - Updated Sep 23 2014 - 1 reports

Similarities In Key Global Markets Allow Pharma To Leverage Payer Value Messaging In Multiple Countries Through "Country Archetypes" Approach

(Date:9/23/2014)... MINNETONKA, Minn. , Sept. 23, 2014   MedNet ... clinical study management systems, is pleased to announce that it ... for Clinical Data Management (SCDM) Annual Conference, to be held ... Las Vegas , Nevada. MedNet team members, ... [Published Bio-Medicine - Sep 23 2014]
First reported Sep 22 2014 - Updated Sep 22 2014 - 1 reports

Research and Markets Adds Report: Analyzing the Generic Drugs Sector of the US Pharmaceutical Industry - 2014

Research and Markets has announced the addition of the "Analyzing the Generic Drugs Sector of the US Pharmaceutical Industry - 2014" report to its offerings.In a release, Research and Markets noted that report highlights include:This research presents ... [Published Individual.com - Sep 22 2014]
First reported Sep 19 2014 - Updated Sep 19 2014 - 1 reports

Actavis Enters New Markets To Boost Profits, Sales

Generic-drugmaker Actavis (ACT) has moved its headquarters to Ireland and is trying to develop its own branded drugs to cut costs and boost revenue. The company, formerly known as Watson Pharmaceuticals, boasts five straight quarters of strong earnings ... [Published Town Hall - Sep 19 2014]
First reported Sep 15 2014 - Updated Sep 15 2014 - 1 reports

U.S. Appeals Court Rejects Presumption of Irreparable Harm in Lanham Act Cases

, the United States Court of Appeals for the Third Circuit held that the presumption of irreparable harm—which traditionally has been applied following a showing of a likelihood of success on the merits in trademark and false advertising cases—no longer ... [Published INTA Bulletin - Sep 15 2014]
First reported Sep 12 2014 - Updated Sep 12 2014 - 1 reports

Parties seeking injunctive relief under Lanham Act

, the U.S. Court of Appeals for the Third Circuit held in Ferring Pharmaceuticals, Inc. v. Watson Pharmaceuticals, Inc. that parties seeking injunctive relief under the Lanham Act will not be afforded a presumption of irreparable harm and must demonstrate ... [Published Lexology - Sep 12 2014]
First reported Sep 10 2014 - Updated Sep 11 2014 - 2 reports

Insider Selling: Actavis plc Insider Sells 6,642 Shares of Stock (ACT)

Actavis plc (NYSE:ACT) Insider Albert Paonessa III sold 6,642 shares of the company’s stock in a transaction that occurred on Monday, September 8th. The stock was sold at an average price of $230.49, for a total value of $1,530,914.58. Following the sale, ... [Published American Banking News - Forex - Sep 11 2014]

Quotes

Zacks’ analyst wrote, "Actavis’ second quarter results were once again strong with the company beating on both the top- and bottom-line. Earnings grew 70.1% to $3.42 per share, beating the Zacks Consensus Estimate of $3.37. Revenues increased 34% to $2.67 billion, beating the Zacks Consensus Estimate of $2.56 billion. We remain optimistic about Actavis’ growth prospects. We are positive on the Forest acquisition which is in line with Actavis’ strategy of building its branded product portfolio. Meanwhile, the upcoming acquisition of Durata should boost Actavis’ infectious disease portfolio. We are encouraged by Actavis’ focus on building its branded and biosimilars pipeline. Based on these positive factors, we are upgrading the stock to Outperform. "
"Reprinted with permission from the October 7, 2014 issue of The Legal Intelligencer. (c) 2014 ALM Media Properties, LLC. Further duplication without permission is prohibited. All rights reserved."
Suren Ajjarapu, Tr x ade Chairman and CEO, stated: "We are very excited to welcome Dr. Ramesh to our team at Tr x ade. Not only will he bring a tighter focus on customer relationship quality to our scientific team/distribution team, but also be a great role model for our employees and vendors who come into contact with him."
Commenting on the event, Jatish Sheth, President, KDPMA, said, "UBM India and KDPMA have worked closely to bring in participation of industry players at the inaugural event of PharmaLytica 2014. Through this industry event, we look forward to showcase Karnataka and the south region of India as a upcoming pharma hub with great potential to build business opportunities within India as well as globally, thus making Karnataka the preferred destination for the pharma sector."

More Content

All (49) | News (39) | Reports (0) | Blogs (6) | Audio/Video (0) | Fact Sheets (4) | Press Releases (0)
sort by: Date | Relevance
Actavis plc Raised to “Outperform” at Zacks (ACT) [Published American Banking News - Oct 18 2014]
Actavis plc Assigned “BBB” Credit Rating (ACT) [Published American Banking News - Oct 17 2014]
Market Update: Actavis plc (NYSE:ACT) – Actavis... [Published Jutia Group - Oct 16 2014]
Standard Heightened for Injunction in Trademark... [Published JD Supra - Oct 09 2014]
Molecular Diagnostics Partnering Terms and Agre... [Published Individual.com - Oct 08 2014]
Actavis, Jazz, Novo Lead Top World Stocks List [Published Crawford Financial Planning - Oct 07 2014]
Borja Arteaga and Albert Fenandez join Blacksto... [Published Funds Society - Oct 06 2014]
Market Update (NYSE:ACT): Actavis to Acquire Du... [Published Jutia Group - Oct 06 2014]
25 Young Companies in the Money [Published Genetic Engineering News - Oct 06 2014]
Trxade : Advances to Direct Sales Model Utilizi... [Published 4 Traders - Sep 30 2014]
Trxade Group, Inc. Advances to Direct Sales Mod... [Published Scottrade - Sep 30 2014]
UBM India Inaugurates PharmaLytica 2014 - Its F... [Published AndhraNews.net - Sep 30 2014]
Acura Pharmaceuticals Hydrocodone Bitartrate Wi... [Published Pettinga Financial Advisors - Sep 29 2014]
Acura Pharmaceuticals Hydrocodone Bitartrate Wi... [Published Street Sweeper - Sep 29 2014]
Stock Update: Actavis plc (NYSE:ACT) – Actavis ... [Published Jutia Group - Sep 26 2014]
Actavis plc Earns BBB Credit Rating (ACT) [Published American Banking News - Sep 26 2014]
UBM India Inaugurates PharmaLytica 2014 - Its F... [Published PR Newswire India - Sep 26 2014]
Third Circuit Rejects Presumption of Irreparabl... [Published JD Supra - Sep 24 2014]
Similarities In Key Global Markets Allow Pharma... [Published Bio-Medicine - Sep 23 2014]
Borja Arteaga and Albert Fenandez join Blacksto... [Published Noodls - Sep 22 2014]
Research and Markets Adds Report: Analyzing the... [Published Individual.com - Sep 22 2014]
Pressure rises to close tax loopholes [Published Irish Independent - Sep 21 2014]
Women With Overactive Bladder Respond Well to O... [Published FirstWord Pharma - Sep 20 2014]
Actavis Enters New Markets To Boost Profits, Sales [Published Town Hall - Sep 19 2014]
U.S. Appeals Court Rejects Presumption of Irrep... [Published INTA Bulletin - Sep 15 2014]
Parties seeking injunctive relief under Lanham Act [Published Lexology - Sep 12 2014]
Research in regulatory science is need of the h... [Published PharmaBiz - Sep 11 2014]
Insider Selling: Actavis plc Insider Sells 6,64... [Published American Banking News - Forex - Sep 11 2014]
Actavis plc Given Average Recommendation of “Bu... [Published American Banking News - Sep 10 2014]
IPA & EDQM to hold 4th technical seminar on Sep... [Published PharmaBiz - Sep 08 2014]
1 2
In Focus
  •  
  •  
  •  
  •  
  •  
  •  
  •  
  •  
  •  
Content Volume
Document Volume
Network
Network

Blogs

sort by: Date | Relevance
Billionaire Eugene Melnyk: I’m a ‘whistleblower... [Published Financial Post - Top Stories - Aug 23 2014]
MONTREAL •Eugene Melnyk, the billionaire owner of the Ottawa Senators and founder of drug maker Biovail Corp., is waging war against the company that now controls his one-time business. Mr. Melnyk alleges that Valeant Pharmaceuticals International Inc. ...
JHL Biotech raises $35 mln Series B funding [Published PE Hub Blog - Jun 20 2014]
Milestone Capital has led a $35 million Series B funding in JHL Biotech, Inc. , a biopharmaceutical company. Milestone was joined by a consortium of venture capitalists and individuals, including President International Corp. , Fubon Financial Holdings ...
NEXT CHOICE ONE DOSE (Levonorgestrel) Tablet [W... [Published DailyMed Drug Label Updates for the last seven ... - May 12 2014]
Updated Date: May 12, 2014 EST ...
NORCO (Hydrocodone Bitartate And Acetaminophen)... [Published DailyMed Drug Label Updates for the last seven ... - May 01 2014]
Updated Date: Apr 30, 2014 EST ...
NORCO (Hydrocodone Bitartate And Acetaminophen)... [Published DailyMed Drug Label Updates for the last seven ... - Apr 30 2014]
Updated Date: Apr 30, 2014 EST ...
1 2
Contact Us
Sales
Support


Freebase CC-BY Some image thumbnails are sourced from Freebase, licensed under CC-BY

Copyright (C) 2014 Silobreaker Ltd. All rights reserved.
The selection and placement of stories and images on any Silobreaker page are determined automatically by a computer program.
The time or date displayed reflects when an article was added to or updated in Silobreaker.